Related Experiment Video

Updated: May 16, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular

Roniel Cabrera1, Miguel Ararat, Yiling Xu

  • 1Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, 1600 SW Archer Rd., P.O. Box 100214, Gainesville, FL 32610-0214, USA. rcabrera@ufl.edu

Cancer Immunology, Immunotherapy : CII
|December 11, 2012
PubMed

Insights

Low doses of sorafenib activate immune effector T cells (Teff) and block regulatory T cells (Tregs) in hepatocellular carcinoma (HCC) patients. This finding reveals potential for novel combination treatments in HCC immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) presents poor tumor immunity, limiting treatment options.
  • Sorafenib is the only approved systemic drug for HCC, but its effects on tumor immunity require further understanding.
  • Developing novel combination therapies, especially with immunologic agents, necessitates knowledge of sorafenib's impact on immune cells.

Purpose of the Study:

  • To investigate the impact of sorafenib on effector T cells (Teff) and regulatory T cells (Tregs) in HCC patients.
  • To determine how different concentrations of sorafenib affect Teff and Treg function and interaction.
  • To explore the potential immune-activating properties of sorafenib in the context of HCC.

Main Methods:

  • Isolation of Teff and Treg from peripheral blood mononuclear cells of HCC patients.
  • Assessment of immune reactivity using thymidine incorporation, ELISA, and flow cytometry.
  • Co-culture of Teff and Treg with varying concentrations of sorafenib.

Main Results:

  • Pharmacologic doses of sorafenib decreased Teff activation by downregulating CD25 expression.
  • Sub-pharmacologic doses of sorafenib significantly increased Teff proliferation and IL-2 secretion.
  • Low-dose sorafenib restored Teff responses in co-cultures by inhibiting Treg suppressive function, correlating with increased IL-2 and IL-6 secretion.

Conclusions:

  • Sub-pharmacologic doses of sorafenib differentially affect T cell subsets in HCC patients, enhancing Teff activation while suppressing Treg function.
  • These findings highlight novel immune-activating properties of low-dose sorafenib.
  • Low-dose sorafenib demonstrates potential for promoting immune responsiveness in HCC, suggesting new avenues for combination immunotherapy.

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...